BRAF rearrangement
Showing 1 - 25 of 562
EGFR-mutant NSCLC Trial in Worldwide (EGF816, trametinib, ribociclib)
Active, not recruiting
- EGFR-mutant Non-small Cell Lung Cancer
- EGF816
- +5 more
-
Toronto, Ontario, Canada
- +10 more
Dec 5, 2022
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life
Recruiting
- Cancer
- +15 more
- Data collection and quality of life questionnaire
-
Graz, Austria
- +40 more
Jul 27, 2021
China With Non-Small-Cell Lung Cancer That is Unable to be
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- (no location specified)
May 16, 2023
Metastatic Lung Cancer Trial in France (InvisionFirst® molecular panel)
Active, not recruiting
- Metastatic Lung Cancer
- InvisionFirst® molecular panel
-
Bayeux, France
- +15 more
Aug 22, 2022
NSCLC Trial in London (MPDL3280A, Vemurafenib, Alectinib)
Recruiting
- Non-small Cell Lung Cancer
- MPDL3280A
- +3 more
-
London, United KingdomUniveristy College London Hospital
Feb 22, 2022
Brain Metastases, MRI Trial in Angers (F-DOPA PET/CT)
Recruiting
- Brain Metastases
- MRI
- F-DOPA PET/CT
-
Angers, France
- +1 more
Dec 28, 2021
Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
- Oral repotrectinib (TPX-0005)
-
Yuma, Arizona
- +175 more
Jan 25, 2023
Patient Journey With Advanced Lung Cancer Positive for ALK
Recruiting
- Carcinoma, Non-Small-Cell Lung
-
Fortaleza, Ceará, Brazil
- +4 more
Sep 26, 2022
Anaplastic Thyroid Cancer Trial in Leiden (dabrafenib/trametinib)
Recruiting
- Anaplastic Thyroid Cancer
-
Leiden, Zuid-Holland, NetherlandsEllen Kapiteijn
Oct 5, 2023
Lung Cancer, Nonsmall Cell Trial in Aurora (Crizotinib)
Completed
- Lung Cancer, Nonsmall Cell
-
Aurora, ColoradoUniversity of Colorado Denver
Jan 19, 2022
Non Small Cell Lung Cancer Trial (HLX208+HLX10)
Not yet recruiting
- Non Small Cell Lung Cancer
- HLX208+HLX10
- (no location specified)
Nov 30, 2022
Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma Trial in Worldwide (Pemigatinib, Gemcitabine, Cisplatin)
Recruiting
- Unresectable Cholangiocarcinoma
- Metastatic Cholangiocarcinoma
- Pemigatinib
- +2 more
-
Phoenix, Arizona
- +212 more
Nov 15, 2022
Melanoma Trial in Boston (MCS110, Dabrafenib, Trametinib)
Active, not recruiting
- Melanoma
- MCS110
- +2 more
-
Boston, MassachusettsDana Farber Cancer Institute
Dec 14, 2022
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,
Recruiting
- Thyroid Gland Anaplastic Carcinoma
- Thyroid Gland Squamous Cell Carcinoma
- Conventional Surgery
- +5 more
-
Stanford, California
- +5 more
Jan 26, 2023
Non-squamous NSCLC Trial in Nanjing (paclitaxel polymeric micelles for injection)
Not yet recruiting
- Non-squamous NSCLC
- paclitaxel polymeric micelles for injection
-
Nanjing, Jiangsu, China
- +1 more
Mar 13, 2023
Stage IV Colorectal Cancer Positive for BRAF V600E Mutation, Colorectal Cancer, Colorectal Cancer Stage IV Trial in Chicago
Recruiting
- Stage IV Colorectal Cancer Positive for BRAF V600E Mutation
- +2 more
- Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab
-
Chicago, IllinoisNorthwestern University
Nov 16, 2022
Advanced Colorectal Cancer Trial in Hangzhou (Cetuximab Dabrafenib Tislelizumab)
Not yet recruiting
- Advanced Colorectal Cancer
- Cetuximab Dabrafenib Tislelizumab
-
Hangzhou, Zhejing, ChinaZhejiang Cancer Institute & Hospital
Jul 19, 2023
Cholangiocarcinoma Trial in Shanghai (Pemigatinib)
Active, not recruiting
- Cholangiocarcinoma
-
Shanghai, Shanghai, ChinaZhongshan Hospital Affiliated to Fudan University
Oct 3, 2022
Low-risk Papillary Thyroid Cancer, Endocrine Malignancy, Thyroid Cancer Trial run by the NCI (Total Thyroidectomy (TT),
Terminated
- Low-risk Papillary Thyroid Cancer
- +2 more
- Total Thyroidectomy (TT)
- Prophylactic central neck lymph node dissection (pCND)
-
Bethesda, MarylandNational Institutes of Health Clinical Center, 9000 Rockville Pi
Sep 8, 2022
Colorectal Cancer, BRAF V600E Mutation Positive Trial (Encorafenib Oral Capsule + Cetuximab)
Not yet recruiting
- Colorectal Cancer
- BRAF V600E Mutation Positive
- Encorafenib Oral Capsule + Cetuximab
- (no location specified)
Jan 30, 2023
MPN (Myeloproliferative Tumors) Trial in Worldwide (Pemigatinib)
Active, not recruiting
- MPN (Myeloproliferative Neoplasms)
-
Phoenix, Arizona
- +32 more
Jun 24, 2022
NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation Trial in Guangzhou (Dabrafenib + Trametinib, Capmatinib)
Not yet recruiting
- NSCLC
- +2 more
- Dabrafenib + Trametinib
- Capmatinib
-
Guangzhou, Guangdong, ChinaCancer Center of Sun-Yat Sen University
Sep 19, 2023